Who Owns Pepto-Bismol?

• Parent Company: Procter & Gamble Company
• Ownership Type: Wholly owned
• Acquisition Year: 1982
• Company Type: Publicly Traded
• Stock Ticker: NYSE: PG

• Founded: 1901
• Founders: Norwich Pharmacal Company
• Acquired by Procter & Gamble Company: 1982

• Founded: 1837
• Headquarters: Cincinnati, Ohio, USA
• Company Type: Publicly Traded
• Stock: NYSE: PG
• Revenue: approximately $84 billion (FY2025)
• Employees: Approximately 107,000

Visit Procter & Gamble Company website

• Headquarters: Cincinnati, Ohio, USA
• Manufacturing / Operations: United States, Mexico, China, India, Various international locations

Pepto-Bismol operates under Procter & Gamble's comprehensive sustainability framework, focusing on responsible manufacturing, packaging sustainability, and product safety. As P&G's leading digestive health medication brand, Pepto-Bismol's sustainability initiatives encompass manufacturing efficiency, environmental responsibility, and ethical product development.

Sustainable Manufacturing: Pepto-Bismol production facilities participate in P&G's global manufacturing sustainability initiatives, which have achieved a 60% reduction in Scope 1 and 2 greenhouse gas emissions since 2010. The brand's manufacturing sites implement advanced energy efficiency programs and are transitioning to renewable energy sources as part of P&G's goal to achieve net zero emissions across operations and supply chains by 2040. These manufacturing improvements reduce the environmental footprint of Pepto-Bismol production while maintaining product quality and safety standards.

Water Conservation: P&G has implemented significant water reduction programs across its manufacturing facilities, including those that produce Pepto-Bismol. The company has committed to reducing water usage in manufacturing by 35% per unit of production by 2030, compared to a 2010 baseline. Pepto-Bismol production facilities participate in these water efficiency initiatives, implementing advanced water recycling systems and water-conscious manufacturing processes that minimize water consumption while maintaining pharmaceutical manufacturing standards.

Packaging Sustainability: Pepto-Bismol packaging is part of P&G's broader initiative to make all packaging reusable, recyclable, or compostable by 2030 and to use at least 50% recycled content in packaging by the same year. The brand has transitioned to more sustainable packaging materials for its liquid bottles, chewable tablet packages, and caplet containers. P&G uses Life Cycle Assessment for package design, ensuring that Pepto-Bismol packaging minimizes environmental impact while protecting product integrity and maintaining child-resistant packaging requirements.

Responsible Sourcing: Pepto-Bismol maintains ethical sourcing standards for its active and inactive ingredients, ensuring suppliers follow fair labor practices and environmental stewardship. The brand's bismuth subsalicylate and other formulation components are sourced from suppliers who comply with P&G's comprehensive supplier code of conduct, which covers human rights, labor practices, and environmental compliance throughout the supply chain.

Product Safety and Quality: Pepto-Bismol maintains high standards of product safety and quality, implementing comprehensive quality control measures and safety protocols. The brand's manufacturing processes follow Current Good Manufacturing Practices (cGMP) for pharmaceutical products, ensuring consistent product quality and consumer safety. P&G publishes annual sustainability reports and implements comprehensive ingredient safety assessment protocols to address consumer and regulatory concerns about over-the-counter medication ingredients.

Pepto-Bismol has earned significant recognition through its market leadership position in the digestive health category and its long-standing reputation as a trusted over-the-counter medication. The brand's awards reflect its position as the #1 pharmacist recommended brand for upset stomach relief and its century-long history of consumer trust.

Pharmacy Times Recognition: Pepto-Bismol has been consistently recognized as the #1 Pharmacist Recommended Upset Stomach Brand in the Pharmacy Times annual survey. Based on the 2024 Pharmacy Times survey in the upset stomach remedies category, Pepto-Bismol maintains its position as the most recommended brand by pharmacists for treating upset stomach, heartburn, indigestion, nausea, and diarrhea. This professional endorsement reflects the trust and confidence healthcare professionals place in Pepto-Bismol's efficacy and safety profile.

Consumer Trust and Brand Loyalty: Pepto-Bismol has earned recognition through over 100 years of consumer trust and brand loyalty. The brand's distinctive pink color and recognizable branding have made it a household name for digestive relief across multiple generations. This long-standing consumer recognition represents a form of brand achievement, reflecting consistent product performance and reliability in treating common digestive complaints.

Market Leadership Position: Pepto-Bismol maintains a leading position in the over-the-counter digestive medication market, consistently ranking among the top-selling brands for upset stomach relief. Market research firms frequently cite Pepto-Bismol as a dominant brand in the digestive health category, reflecting strong consumer preference and brand recognition built over decades of market presence.

P&G Internal Recognition: Within Procter & Gamble's portfolio, Pepto-Bismol has been recognized as one of the company's successful health care brands, contributing to P&G's leadership in the over-the-counter medication segment. The brand's consistent performance and innovation in digestive health formulations have earned it recognition as a key asset in P&G's Health Care division.

Product Innovation Recognition: Pepto-Bismol's development of various formulation formats, including liquid, chewable tablets, caplets, and maximum strength versions, represents innovation in delivering digestive relief in consumer-preferred formats. The brand's ability to maintain product efficacy across different delivery systems while ensuring safety and convenience demonstrates ongoing innovation in over-the-counter medication delivery.

Reye's Syndrome Warning and Pediatric Use: Pepto-Bismol has faced significant controversy regarding its use in children due to the risk of Reye's syndrome. Since 2003, the FDA has urged that anyone under 12 should avoid Pepto-Bismol because its active ingredient, bismuth subsalicylate, is a derivative of aspirin. The use of salicylates in children with viral illnesses, particularly influenza or chickenpox, has been associated with Reye's syndrome, a rare but serious condition that causes swelling in the liver and brain. This warning has led to increased scrutiny of Pepto-Bismol's marketing and labeling, requiring prominent warnings about pediatric use contraindications.

FDA Regulatory Oversight: As an over-the-counter medication containing bismuth subsalicylate, Pepto-Bismol is subject to ongoing FDA regulatory oversight. The brand must maintain compliance with FDA monograph requirements for antacid and anti-diarrheal medications. While no major product recalls have been issued recently, Pepto-Bismol, like all OTC medications, must maintain vigilance regarding potential safety issues and adverse event reporting.

Drug Interaction Concerns: Pepto-Bismol has faced scrutiny regarding potential drug interactions, particularly with other medications that affect bleeding or contain salicylates. The bismuth subsalicylate in Pepto-Bismol can interact with blood thinners, diabetes medications, and other drugs, creating potential safety concerns for consumers taking multiple medications. These interaction risks require clear labeling and consumer education about safe use practices.

Ingredient Safety Questions: Pepto-Bismol has occasionally faced questions about the safety of bismuth subsalicylate, particularly regarding long-term use and potential side effects such as black tongue or black stools. While these side effects are generally harmless and temporary, they have raised consumer concerns that require educational efforts and clear communication about expected versus adverse effects.

Environmental Impact of Packaging: Like many liquid medications, Pepto-Bismol has faced scrutiny regarding the environmental impact of its plastic bottles and packaging materials. Environmental advocates have raised concerns about plastic waste from over-the-counter medication packaging. In response, P&G has developed sustainability initiatives including recycled content in packaging and participation in broader packaging recycling programs.

Temperature-Sensitive Shipping Requirements: Pepto-Bismol products require strict temperature control during shipping and storage to maintain product efficacy and safety. Products like Pepto-Bismol need temperature-sensitive handling, and any lapse in cold chain management risks product spoilage. These requirements create logistical challenges and environmental concerns related to refrigerated shipping and storage, though P&G has implemented robust quality control measures to address these issues.